Page 10 - 80_02

NOTICIAS
CIENTÍFICAS…

8.
Lin,
T.
I;
Lenz,
O;
Fanning,
G;
Verbinnen,
T;
Delouvroy,
F;
Scholliers,
A;
Vermeiren,
K;

Rosenquist,
A;
Edlund,
M;
Samuelsson,
B.;
Vrang,
L.;
De
Kock,
H.;
Wigerinck,
P.;
Raboisson,

P.;
Simmen,
K.
(2009)
"In
vitro
activity
and
preclinical
profile
of
TMC435350,
a
potent

hepatitis
C
virus
protease
inhibitor"
Antimicrob.
Agents
and
Chemother.,
53,
1377-­-1385.

9.
Gao,
M.;
Nettles,
R.
E.;
Belema,
M.;
Zinder,
L.
B.;
Nguyen,
V.
N.;
Fridell,
R.
A.;
Serrano-­-Wu,
M.

H.;
Langley,
D.
R.;
Sun,
J.
H.;
O'Boyle,
D.
R.;
Lemm,
J.
A.;
Wang,
C.;
Knipe,
J.
O.;
Chien,
C.;

Colonno,
R.
J.;
Grasela,
D.
M.;
Meanwell,
N.
A.;
Hamann,
L.
G.
(2010)
“Chemical
genetics

strategy
identifies
an
HCV
NS5A
inhibitor
with
a
potent
clinical
effect”
Nature,
465,
96-­-
100.

10.
Lok,
A.
S.;
Gardiner,
D.
F.;
Lawitz,
E.;
Martorell,
C.;
Everson,
G.
T.;
Ghalib,
R.;
Reindollar,
R.;

Rustgi,
V.;
McPhee,
F.;
Wind-­-Rotolo,
M.;
Persson,
A.;
Zhu,
K.;
Dimitrova,
D.
I.;
Eley,
T.;
Guo,

T.;
Grasela,
D.
N.;
Pasquinelli,
C.;
(2012)
“Preliminary
Study
of
Two
Antiviral
Agents
for

Hepatitis
C
Genotype
1”,
New
Engl.
J.
Med.
366,
216-­-224.

11.
Lupberger,
J.;
Zeisel,
M.
B.;
Xiao,
F.;
Thumann,
Ch.;
Fofana,
I.;
Zona,
L.;
Davis,
Ch.;
Mee,
Ch.
J.;

Turek,
M.;
Gorke,
S.;
Royer,
C.;
Fischer,
B.;
Zahid,
M.
N.;
Lavillette,
D.;
Fresquet,
J.;
Cosset,
F.-­-
L.;
Rothenberg,
S.
M.;
Pietschmann,
T.;
Patel,
A.
H.;
Pessaux,
P.;
Doffoël,
M.;
Raffelsberger,

W.;
Poch,
O.;
McKeating,
J.
A.;
Brino,
L.;
et
al.
(2011)
“EGFR
and
EphA2
are
host
factors
for

hepatitis
C
virus
entry
and
possible
targets
for
antiviral
therapy”
Nature
Medicine,
17,
589-­-
595.

12.
Sulkowski,
M.
S.;
Kang,
M.;
Matining,
R.;
Wyles,
D.;
Johnson,
V.
A.;
Morse,
G.
D.;
Amorosa,
V.;

Bhattacharya,
D.;
Coughlin,
K.;
Wong-­-Staal,
F.;
Glesby,
M.
J.;
(2014)
“Safety
and
Antiviral

Activity
of
the
HCV
Entry
Inhibitor
ITX5061
in
Treatment-­-Naive
HCV-­-Infected
Adults:
A

Randomized,
Double-­-Blind,
Phase
1b
Study”,
J.
Infect.
Dis.
209,
658-­-667.

13.
Ferenci,
P.;
Bernstein,
D.;
Lalezari,
J.;
Cohen,
D.;
Luo,
Y.;
Cooper,
C.;
Tam,
E.;
Marinho,
R.
T.;

Tsai,
N.;
Nyberg,
A.;
Box,
T.
D.;
Younes,
Z.;
Enayati,
P.;
Green,
S.;
Baruch,
Y.;
Bhandari,
B.
R.;

Caruntu,
F.
A.;
Sepe,
T.;
Chulanov,
V.;
Janczewska,
E.;
Rizzardini,
G.;
Gervain,
J.;
Planas,

Planas;
Moreno,
Ch.;
Hassanein,
T.;
Xie,
W.;
King,
M.;
Podsadecki,
T.;
Reddy,
K.
R.;
(2014)

“ABT-­-450/r–Ombitasvir
and
Dasabuvir
with
or
without
Ribavirin
for
HCV”,
New
Eng.
J.

Med.
DOI:
10.1056/NEJMoa1402338.

249